Live prices from 2 SA suppliers, from R400.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 2 prices for PE-22-28. Cheapest: R400.00. Average: R485.00.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
Crono Pharm
Best
PE-22-28 |
R400.00 | R40.00/mg | In Stock | R150.00 |
Lab Tested
|
— | ||
|
PE-22-28 10mg |
R570.00 | R57.00/mg | In Stock | R120.00 |
—
|
— |
More ways to compare PE-22-28
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
TREK-1 Channel Blocker | Shortened Spadin Analog
Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.
Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.
GVSWGL?
Glycine
Position 1
Valine
Position 2
Serine
Position 3
Tryptophan
Position 4
Glycine
Position 5
Leucine
Position 6
Arg (GVSWGLR)
Position 7
Primary research focus with rapid effects in behavioral models within 4 days.
Anxiolytic properties demonstrated in preclinical anxiety models.
Nearly doubles BrdU-positive cells after 4-day treatment.
Promotes new synapse formation through CREB activation.
Hippocampal and prefrontal cortex TREK-1 expression supports memory.
Potential ischemic protection and neuronal survival support.
Subcutaneous injection to abdominal fat or thigh with site rotation.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antidepressant Effect | 50-200mcg | Once daily | SubQ |
| Neurogenesis Support | 100-200mcg | Once daily | SubQ |
Limited data from animal studies only; higher doses required than injection.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Use | Higher than injectable (specific dose TBD) | Daily | Oral |
Theoretical route; unstudied for PE-22-28 specifically.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Use | 100-300mcg (estimated) | Daily | Intranasal |
Both enhance serotonergic pathways; monitor for excessive activity.
Complementary neurogenesis and cognitive support.
Different mechanisms for anxiety and mood support.
Complementary neuroplasticity pathways.
Different mechanisms, no contraindications.
Serotonin syndrome risk.
Measurable antidepressant effects in preclinical models
Neurogenesis and synaptogenesis processes established
Potential mood and cognitive improvements emerge
Sustained treatment allows full neurogenic effects
PE-22-28 IC50 0.12 nM vs 40-60 nM for Spadin; ~23 hour duration. Frontiers in Pharmacology.
Original discovery of TREK-1 blockade as antidepressant mechanism. PLOS Biology.
TREK-1 knockout mice show depression-resistant behavior in 5 tests. Nature Neuroscience.
Plain-English guides and study summaries from published literature.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.
